The multiplicity of potential biomarkers that have been established (PD‐L1 expression, TMB, and dMMR status), as well as the effective integration of pembrolizumab in the first‐line treatment of BRAF mutant melanoma patients, should prompt further investigations in EGFR mutant treatment‐naïve NSCLC patients. The gene discussed is CD274; the disease is melanoma.